This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC. All patients are infused with their autologous TIL (LN-145) followed by IL-2 administration between 3-24 hours after every 8-12 hours for a total of 6 doses. Cohort 1 will consist of patients whose tumors did not express PD-L1 (tumor proportion score [TPS] < 1%) prior to their CPI treatment. Cohort 2 will consist of those who do express PD-L1. Cohort 3 will consist of patients whose tumors do not express PD-L1 (TPS < 1%) prior to their CPI treatment and who are unable to safely undergo a surgical harvest for TIL generation. The primary outcome measured will be objective response rate.
(IOV-LUN-202 , IRB 2020-1030)